编号：2024-07 1 证券代码： 000516 证券简称： 国际医学 西安国际医学投资股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown stable revenue growth, continuously enhancing its operational strength [1] - The company reported total revenue of 3.606 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 7.85%, while the net profit attributable to the parent company was -0.212 billion yuan, an increase of 4.59% [1] - In Q3 alone, the company achieved total revenue of 1.186 billion yuan, up 4.58% year-on-year, and the net profit attributable to the parent company was -0.385 billion yuan, a reduction in loss by 44% compared to Q2 2024 [1] - The company has entered into a strategic cooperation with CHA Medical Group from South Korea to enhance cross-border medical services [1] Financial Performance Summary - The company is expected to achieve total revenues of 5.454 billion yuan, 6.385 billion yuan, and 7.210 billion yuan for the years 2024, 2025, and 2026 respectively, with year-on-year growth rates of 18.1%, 17.1%, and 12.9% [2][5] - The net profit attributable to the parent company is projected to be -0.235 billion yuan, -0.054 billion yuan, and 0.019 billion yuan for the years 2024, 2025, and 2026 respectively, with year-on-year growth rates of 36.2%, 77.0%, and 135.7% [2][5] - The gross profit margin is expected to improve from 10.4% in 2024 to 13.1% in 2026 [2][5] - The company’s operating cash flow is projected to be 1.087 billion yuan in 2024, with a gradual increase in subsequent years [3] Key Financial Ratios - The company’s return on equity (ROE) is expected to improve from -6.4% in 2024 to 0.5% in 2026 [2][5] - The price-to-earnings (P/E) ratio is projected to be 636.05 in 2026, indicating a significant increase in valuation [2][5] - The debt-to-asset ratio is expected to be 68.2% in 2024, slightly increasing to 68.6% in 2026 [5]

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Insights - The company reported a revenue of 3.606 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 7.85%. The net profit attributable to shareholders was -212 million yuan, an increase of 4.59% compared to the previous year [3][5] - The company has been optimizing its specialized layout and enhancing international cooperation, including a strategic partnership with Korea's CHA Medical Group to establish China's first referral center [4][5] - The company's gross profit margin for the first three quarters of 2024 was 9.19%, showing a slight increase, while the management and financial expense ratios have significantly decreased, indicating improved operational efficiency [3][4] Financial Performance Summary - For 2024, the company expects revenues of 5.054 billion yuan, 5.666 billion yuan, and 6.329 billion yuan for the years 2024, 2025, and 2026 respectively, with net profits projected at -255 million yuan, 20,000 yuan, and 185 million yuan for the same years [5][6] - The company’s EBITDA is forecasted to grow from 580.35 million yuan in 2024 to 1.13662 billion yuan in 2026, indicating a positive trend in operational profitability [6][8] - The report highlights a projected increase in the company's net profit margin from -5.0% in 2024 to 2.9% in 2026, reflecting a turnaround in profitability [6][8]

证券代码：000516 证券简称：国际医学 公告编号：2024-063 | 世纪 | 616,061,198 | 27.25% | 402,660,0 | 440,460,0 | 71.50% | 19.49% | 0 | 0.00% | 0 | 0.00% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 新元 申华 | | | 00 | 00 | | | | | | | | 控股 | | | 52,400,00 | 52,400,00 | | | | | | | | 集团 | 60,486,283 | 2.68% | 0 | 0 | 86.63% | 2.32% | 0 | 0.00% | 0 | 0.00% | | 有限 | | | | | | | | | | | | 公司 | | | | | | | | | | | | 曹鹤 | | | | | | | | | | | | 玲 | 42,097,770 | 1.86% | 0 | 0 | 0.00% | 0.00% | 0 | 0.00% | 31,573,3 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥1,185,795,210.25, representing a 4.58% increase year-over-year[3] - The net profit attributable to shareholders was -¥38,503,140.17, a significant decrease of 60,252.12% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥80,627,749.25, an increase of 14.85% year-over-year[3] - Total operating revenue for Q3 2024 reached ¥3,606,256,924.42, an increase of 7.85% compared to ¥3,343,661,725.08 in Q3 2023[13] - The net loss for Q3 2024 was ¥294,272,771.90, compared to a net loss of ¥283,231,471.38 in Q3 2023, indicating a decline in profitability[14] - The company reported a basic and diluted earnings per share of -0.0954 for Q3 2024, compared to -0.0983 for the same period last year[14] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,554,066,876.37, down 6.78% from the end of the previous year[3] - The company's total assets decreased to ¥10,554,066,876.37 from ¥11,321,135,811.77, representing a decline of 6.77% year-over-year[12] - Total liabilities decreased to ¥7,075,540,848.59 from ¥7,505,045,119.83, a reduction of 5.73% compared to the previous year[12] - Shareholders' equity attributable to the parent company decreased to ¥3,652,616,319.10, a decline of 6.54% compared to the previous year[3] - The equity attributable to shareholders of the parent company was ¥3,652,616,319.10, while total equity amounted to ¥3,478,526,027.78[12] Cash Flow - Cash flow from operating activities for the year-to-date was ¥623,687,115.87, reflecting a decrease of 9.50% year-over-year[3] - The net cash flow from operating activities decreased to CNY 623,687,115.87 from CNY 689,153,979.24, reflecting a decline of 9.5%[15] - Cash inflow from operating activities for the current period was CNY 3,544,589,105.11, an increase of 8.3% compared to CNY 3,271,420,242.69 in the previous period[15] - The net cash flow from investing activities was negative at CNY -406,156,113.17, improving from CNY -616,922,958.32 in the previous period[15] - Cash inflow from financing activities totaled CNY 557,630,000.00, down from CNY 680,000,000.00, a decrease of 18.0%[16] - The net cash flow from financing activities was negative at CNY -734,010,695.10, worsening from CNY -469,134,181.46 in the previous period[16] Expenses - Total operating costs for Q3 2024 were ¥3,892,721,588.98, up from ¥3,731,857,156.74 in the same period last year, reflecting a year-over-year increase of 4.31%[13] - Research and development expenses decreased by 40.05% year-to-date compared to the same period last year[6] - Research and development expenses for Q3 2024 were ¥5,715,774.18, down from ¥9,533,885.43 in Q3 2023, showing a decrease of 40.5%[13] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 107,360[7] - The company held 10,997,100 shares in its repurchase account, accounting for 0.49% of the total share capital[8] Current Assets - The total current assets decreased from CNY 1,912,895,613.76 to CNY 1,461,576,314.49, a decline of approximately 23.5%[10] - Cash and cash equivalents dropped significantly from CNY 943,962,638.82 to CNY 427,482,946.42, representing a decrease of about 54.7%[10] - Accounts receivable increased from CNY 661,684,668.02 to CNY 753,350,686.68, showing a growth of approximately 13.8%[10] - Inventory rose from CNY 78,336,971.70 to CNY 98,559,720.86, an increase of around 25.8%[10] - The total non-current assets decreased to ¥9,092,490,561.88 from ¥9,408,240,198.01, a decline of 3.35% year-over-year[12] Other Income and Expenses - The company reported a 429.52% increase in other income year-to-date, primarily due to debt restructuring gains[6] - The company reported a significant increase in prepaid expenses from CNY 6,869,617.24 to CNY 11,988,100.36, a rise of approximately 74.0%[10] Product Development and Strategy - The company did not disclose any new product developments or market expansion strategies during the conference call[9]

大家好 欢迎参加东海证券海盐行业洞察第十一期国际医学深度报告分享目前所谓患者均处于静音状态下面开始公演的声明声明完毕后主持人可直接开始发言 东海证券研究所提醒您本次电话会议仅面向机构投资者或受邀客户会议中发表的所有相关信息观点分析及预测仅供参考之用作为投资建议和依据参会者应基于自身判断和投资需求审慎作出投资决策并自行承担由此产生的风险和责任未经合法授权许可严禁通过任何途径任何形式对本次会议内容信息进行传播转载及相关解读 本公司对涉嫌违反上述情形的行为保留追究法律责任的权利感谢您的理解和支持可以了吧 各位投资者大家下午好我是东海证券的医药分析师杜永鹏前几天的话我们发布了一篇国际疫情的一个深度报告今天我们就要报告的一个具体内容给大家做一个汇报和解读 国际医学经过20多年的发展的话目前已成为一个西北地区的一个全科医疗的龙头型企业从床位数据也超过了1万家然后公司也积累了丰富的一个民营医院的一个建设运营经验目前有高新医院和中心院两大院区 从收入端来看过去几年公司保持了一个快速的一个增长啊19年的话公司营业收入的不足不足十亿元截止到2023年的时候的话已经超过46亿元过去几年的互合增速也超过40% 因为从利用端的话公司过 ...

证券代码：000516 证券简称：国际医学 公告编号：2024-061 西安国际医学投资股份有限公司 关于2021年限制性股票激励计划第三个解除 限售期解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次符合解除限售条件的激励对象人数：460 人； 2、本次解除限售的限制性股票数量为 9,293,404 股，占目前公司总股本的 0.4111%； 3、本次解除限售的限制性股票的上市流通日为 2024 年 10 月 17 日。 西安国际医学投资股份有限公司（以下简称"公司"）于 2024 年 4 月 24 日 召开第十二届董事会第十五次会议和第十一届监事会第十一次会议，审议通过了 《关于公司 2021 年限制性股票激励计划第三个解除限售期及 2022 年限制性股票 激励计划第二个解除限售期解除限售条件成就的议案》，本次符合解除限售条件 的激励对象共 460 人，可申请解除限售的限制性股票数量为 9,293,404 股，占公司 总股本的 0.4111%。 公司已按照相关规定办理了上述限制性股票的解除限售及上市流通事宜，有 ...

证券代码：000516 证券简称：国际医学 公告编号：2024-060 西安国际医学投资股份有限公司 关于股份回购进展公告 本公司及董事会全体成员保证公告内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"本公司"或"公司"） 于2024年4月24日召开第十二届董事会第十五次会议，并于2024年5月20 日召开2023年度股东大会，审议通过了《关于回购公司股份方案的议案》 及《关于提请股东大会授权董事会办理本次回购相关事宜的议案》，决 定使用自有资金以集中竞价交易方式回购已发行的人民币普通股（A股） 股票，回购的股份将全部用于注销以减少公司注册资本。本次回购的资 金总额不低于人民币10,000万元（含）且不超过人民币15,000万元（含）， 回购价格不超过人民币9.16元/股（含），具体回购股份的数量以回购 结束时实际回购的股份数量为准。回购期限为自公司股东大会审议通过 本次回购方案之日起12个月内。公司已在中国证券登记结算有限责任公 司深圳分公司开立股份回购专用证券账户。具体内容详见公司分别于 2024年4月26日和5月21日在《中国证券报》《上海证券报》 ...

Investment Rating - The report maintains a "Buy" rating for the company International Medicine (000516) as of October 5, 2024 [2]. Core Insights - The company has established strategic partnerships with international medical institutions, including a collaboration with Korea's CHA Medical Group to set up China's first referral center, enhancing its cross-border medical service capabilities [3]. - A partnership with Mayo Clinic has been formed to improve clinical, research, and educational capabilities, positioning the company as a member of a prestigious global medical alliance [4]. - Revenue forecasts for 2024-2026 are projected at 52.4 billion, 59.7 billion, and 68.2 billion yuan respectively, with net profits expected to turn positive by 2026 [5]. Financial Summary - The company's revenue for 2023 is reported at 4,618 million yuan, with a growth rate of 70.34%. Projections for 2024, 2025, and 2026 are 5,240 million, 5,970 million, and 6,820 million yuan, reflecting growth rates of 13.48%, 13.93%, and 14.24% respectively [5][7]. - The net profit attributable to the parent company is expected to improve from -368.36 million yuan in 2023 to 188.02 million yuan in 2026, indicating a significant turnaround [5][7]. - The company's price-to-sales (P/S) ratio is projected to decrease from 2.67 in 2023 to 1.81 by 2026, suggesting a more favorable valuation over time [5][7].

Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Views - The company is a leading general medical service provider in Northwest China, with a strong focus on expanding its medical business and achieving profitability [6][17]. - The company has shown significant revenue growth, with a compound annual growth rate (CAGR) of 46.93% from 2019 to 2023, and is expected to continue this trend [6][21]. - The company is transitioning towards profitability, with a notable reduction in losses and an increase in revenue from its high-end hospital and center hospital operations [6][24]. Summary by Sections Company Overview - The company has been deeply involved in the medical industry for over 20 years, operating two major hospitals: the High-tech Hospital and the International Medical Center Hospital, which serve as a comprehensive medical service platform in Northwest China [6][17]. High-tech Hospital - The High-tech Hospital is recognized as the first social-run tertiary hospital in China, with a strong reputation in Northwest China and a patient inflow from outside the region [6][30]. - The hospital has maintained a steady growth rate of over 10% in revenue, with a historical average net profit margin of around 14% [6][30]. - In 2023, the hospital's revenue reached 1.485 billion yuan, with a year-on-year growth of 50.5% [6][33]. Center Hospital - The Center Hospital, built to tertiary standards, has a total of 8,637 beds and is positioned to significantly increase patient volume and revenue [6][38]. - The hospital offers a wide range of services, including serious medical care and consumer-oriented medical services, enhancing patient retention [6][38]. - The Center Hospital is expected to achieve a revenue scale of 10 billion yuan in the medium to long term, driven by increasing patient volumes and operational efficiency [6][38]. Financial Projections - The company forecasts revenues of 5.141 billion yuan, 6.152 billion yuan, and 7.524 billion yuan for 2024, 2025, and 2026, respectively, with a gradual improvement in net profit [6][9]. - The company aims to narrow its losses significantly, with projected net profits of -230 million yuan in 2024, -39 million yuan in 2025, and a positive 97 million yuan in 2026 [6][9].